Funing Center for Disease Control and Prevention
Welcome,         Profile    Billing    Logout  
 10 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhu, Fengcai
NCT04526990: Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

Completed
3
44247
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo
CanSino Biologics Inc., Beijing Institute of Biotechnology
COVID-19
08/21
10/22
NCT04887207: A Global Phase III Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells)

Not yet recruiting
3
40000
NA
Recombinant COVID-19 vaccine (Sf9 cells), Placebo control
Jiangsu Province Centers for Disease Control and Prevention, WestVac Biopharma Co., Ltd., West China Hospital
COVID-19
02/22
12/22
NCT05204589: Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine

Completed
3
10285
RoW
Aerosolized Ad5-nCoV, Inactivated SARS-CoV-2 vaccine
Jiangsu Province Centers for Disease Control and Prevention, Anhui Provincial Center for Disease Control and Prevention, Shandong Province Centers for Disease Control and Prevention, Hunan Provincial Center for Disease Control and Prevention, Yunnan Center for Disease Control and Prevention, Chongqing Center for Disease Control and Prevention
COVID-19
04/22
10/22
NCT05124561: Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

Withdrawn
3
13000
NA
Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), Placebo
CanSino Biologics Inc., Beijing Institute of Biotechnology
COVID-19
04/22
08/22
NCT06175494: A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

Recruiting
3
4800
RoW
Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell), Recombinant COVID-19 Variant Vaccine (Sf9 Cell), Placebo
WestVac Biopharma Co., Ltd., WestVac Biopharma (Guangzhou) Co., Ltd.
COVID-19
07/24
01/25
NCT06088745: A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine

Recruiting
3
4
RoW
Recombinant Herpes Zoster Vaccine, LZ901, Recombinant Herpes Zoster Vaccine Placebo
Beijing Luzhu Biotechnology Co., Ltd.
Vaccine-Preventable Diseases, Herpes Zoster
12/24
12/26
NCT05330624: Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens

Active, not recruiting
2b
720
RoW
plague vaccine(F1+rV)
Jiangsu Province Centers for Disease Control and Prevention
Plague
05/22
09/22
NCT05060484: A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting
2
1800
RoW
SCT1000, Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells), Gardasil®9, Gardasil®, placebo
Sinocelltech Ltd.
Interventional, Prevention, Randomized
05/22
07/22
NCT04813562: Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

Recruiting
2
480
RoW
a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56, a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56, a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56, a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56, a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56, a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56, a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56, a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56
Jiangsu Province Centers for Disease Control and Prevention, Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE Biotech Co, Ltd. LIAONINGMAOKANGYUAN Biotech Co, Ltd
COVID-19
07/22
07/22
NCT05663086: Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above

Withdrawn
2
720
RoW
One dose group, Two doses group, Aged 18-59 years, Aged 60 years old and above
Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd.
COVID-19
06/23
06/23
NCT05939648: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Active, not recruiting
2
450
RoW
SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline
AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co., Ltd.
SARS-CoV-2
11/23
12/24
NCT04840992: Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

Completed
1/2
840
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo for Inhalation, Placebo
CanSino Biologics Inc., Beijing Institute of Biotechnology, Jiangsu Province Centers for Disease Control and Prevention
COVID-19
07/22
08/22
NCT05013983: Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents

Withdrawn
1/2
600
RoW
Recombinant COVID-19 vaccine (Sf9 cells), Placebo control
WestVac Biopharma Co., Ltd., West China Hospital
COVID-19
12/24
12/25
NCT04636333: Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)

Recruiting
1
216
RoW
Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28, Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28, Two doses of placebo at the schedule of day 0, 14 #middle-dose group#, Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#, Two doses of placebo at the schedule of day 0, 14 #High-dose group#, Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Jiangsu Province Centers for Disease Control and Prevention, Academy of Military Medical Sciences，Academy of Military Sciences，PLA, ZHONGYIANKE Biotech Co, Ltd., LIAONINGMAOKANGYUAN Biotech Co, Ltd
COVID-19
12/21
07/22
NCT04921111: A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting
1
240
RoW
SCT1000, Recombinant 14 valent Human Papillomavirus Vaccine, Gardasil®9, Recombinant 9 valent human papillomavirus vaccine, placebo, aluminium phosphate, Gardasil®, Recombinant 4 valent human papillomavirus vaccine
Sinocelltech Ltd.
HPV Infection Vaccine Safety SCT1000
07/22
10/22
NCT05552573: Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

Active, not recruiting
1
100
RoW
low-dose LYB001, Recombinant COVID-19 Vaccine (CHO Cell), high-dose LYB001
Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd.
COVID-19
01/23
12/23
NCT05939596: A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Active, not recruiting
1
60
RoW
SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline
AIM Vaccine Co., Ltd., First Affiliated Hospital Bengbu Medical College
SARS-CoV-2
09/23
08/24
NCT04916886: A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.

Completed
N/A
2021
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
CanSino Biologics Inc., Jiangsu Province Centers for Disease Control and Prevention
COVID-19
07/22
07/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhu, Fengcai
NCT04526990: Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

Completed
3
44247
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo
CanSino Biologics Inc., Beijing Institute of Biotechnology
COVID-19
08/21
10/22
NCT04887207: A Global Phase III Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells)

Not yet recruiting
3
40000
NA
Recombinant COVID-19 vaccine (Sf9 cells), Placebo control
Jiangsu Province Centers for Disease Control and Prevention, WestVac Biopharma Co., Ltd., West China Hospital
COVID-19
02/22
12/22
NCT05204589: Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine

Completed
3
10285
RoW
Aerosolized Ad5-nCoV, Inactivated SARS-CoV-2 vaccine
Jiangsu Province Centers for Disease Control and Prevention, Anhui Provincial Center for Disease Control and Prevention, Shandong Province Centers for Disease Control and Prevention, Hunan Provincial Center for Disease Control and Prevention, Yunnan Center for Disease Control and Prevention, Chongqing Center for Disease Control and Prevention
COVID-19
04/22
10/22
NCT05124561: Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

Withdrawn
3
13000
NA
Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), Placebo
CanSino Biologics Inc., Beijing Institute of Biotechnology
COVID-19
04/22
08/22
NCT06175494: A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

Recruiting
3
4800
RoW
Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell), Recombinant COVID-19 Variant Vaccine (Sf9 Cell), Placebo
WestVac Biopharma Co., Ltd., WestVac Biopharma (Guangzhou) Co., Ltd.
COVID-19
07/24
01/25
NCT06088745: A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine

Recruiting
3
4
RoW
Recombinant Herpes Zoster Vaccine, LZ901, Recombinant Herpes Zoster Vaccine Placebo
Beijing Luzhu Biotechnology Co., Ltd.
Vaccine-Preventable Diseases, Herpes Zoster
12/24
12/26
NCT05330624: Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens

Active, not recruiting
2b
720
RoW
plague vaccine(F1+rV)
Jiangsu Province Centers for Disease Control and Prevention
Plague
05/22
09/22
NCT05060484: A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting
2
1800
RoW
SCT1000, Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells), Gardasil®9, Gardasil®, placebo
Sinocelltech Ltd.
Interventional, Prevention, Randomized
05/22
07/22
NCT04813562: Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

Recruiting
2
480
RoW
a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56, a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56, a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56, a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56, a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56, a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56, a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56, a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56
Jiangsu Province Centers for Disease Control and Prevention, Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE Biotech Co, Ltd. LIAONINGMAOKANGYUAN Biotech Co, Ltd
COVID-19
07/22
07/22
NCT05663086: Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above

Withdrawn
2
720
RoW
One dose group, Two doses group, Aged 18-59 years, Aged 60 years old and above
Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd.
COVID-19
06/23
06/23
NCT05939648: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Active, not recruiting
2
450
RoW
SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline
AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co., Ltd.
SARS-CoV-2
11/23
12/24
NCT04840992: Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

Completed
1/2
840
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo for Inhalation, Placebo
CanSino Biologics Inc., Beijing Institute of Biotechnology, Jiangsu Province Centers for Disease Control and Prevention
COVID-19
07/22
08/22
NCT05013983: Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents

Withdrawn
1/2
600
RoW
Recombinant COVID-19 vaccine (Sf9 cells), Placebo control
WestVac Biopharma Co., Ltd., West China Hospital
COVID-19
12/24
12/25
NCT04636333: Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)

Recruiting
1
216
RoW
Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28, Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28, Two doses of placebo at the schedule of day 0, 14 #middle-dose group#, Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#, Two doses of placebo at the schedule of day 0, 14 #High-dose group#, Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Jiangsu Province Centers for Disease Control and Prevention, Academy of Military Medical Sciences，Academy of Military Sciences，PLA, ZHONGYIANKE Biotech Co, Ltd., LIAONINGMAOKANGYUAN Biotech Co, Ltd
COVID-19
12/21
07/22
NCT04921111: A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting
1
240
RoW
SCT1000, Recombinant 14 valent Human Papillomavirus Vaccine, Gardasil®9, Recombinant 9 valent human papillomavirus vaccine, placebo, aluminium phosphate, Gardasil®, Recombinant 4 valent human papillomavirus vaccine
Sinocelltech Ltd.
HPV Infection Vaccine Safety SCT1000
07/22
10/22
NCT05552573: Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

Active, not recruiting
1
100
RoW
low-dose LYB001, Recombinant COVID-19 Vaccine (CHO Cell), high-dose LYB001
Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd.
COVID-19
01/23
12/23
NCT05939596: A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Active, not recruiting
1
60
RoW
SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline
AIM Vaccine Co., Ltd., First Affiliated Hospital Bengbu Medical College
SARS-CoV-2
09/23
08/24
NCT04916886: A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.

Completed
N/A
2021
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
CanSino Biologics Inc., Jiangsu Province Centers for Disease Control and Prevention
COVID-19
07/22
07/22

Download Options